Spots Global Cancer Trial Database for avutometinib
Every month we try and update this database with for avutometinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | NCT06394804 | Low-Grade Serou... | Avutometinib Defactinib Letrozole | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | NCT06194929 | Melanoma | Defactinib Avutometinib Encorafenib | 18 Years - | University of Utah | |
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | NCT06394804 | Low-Grade Serou... | Avutometinib Defactinib Letrozole | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Avutometinib for People With Solid Tumor Cancers | NCT06104488 | Refractory Canc... CNS Tumors CNS Tumor, Adul... CNS Tumor, Chil... MAP Kinase Fami... NF1 Plexiform Neuro... Low-grade Gliom... Optic Pathway G... Neuroblastoma Primary Brain T... Solid Tumor Solid Tumor, Ad... Solid Carcinoma Central Nervous... | Avutometinib | 3 Years - 30 Years | Memorial Sloan Kettering Cancer Center | |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | NCT06072781 | Low Grade Serou... | avutometinib Defactinib Pegylated lipos... Paclitaxel Topotecan Letrozole Anastrozole | 18 Years - | Verastem, Inc. | |
| A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | NCT05512208 | Endometrioid Ca... Mucinous Ovaria... High Grade Sero... Cervical Cancer Solid Tumor | Avutometinib (V... | 18 Years - 99 Years | University of Oklahoma | |
| Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | NCT05798507 | Glioblastoma Recurrent Gliob... | Avutometinib Biospecimen Col... Defactinib | 21 Years - | Emory University | |
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | NCT06394804 | Low-Grade Serou... | Avutometinib Defactinib Letrozole | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer | NCT06369259 | Advanced Colore... | Defactinib Cetuximab Avutometinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | NCT06394804 | Low-Grade Serou... | Avutometinib Defactinib Letrozole | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | NCT06194929 | Melanoma | Defactinib Avutometinib Encorafenib | 18 Years - | University of Utah | |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | NCT06194929 | Melanoma | Defactinib Avutometinib Encorafenib | 18 Years - | University of Utah |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
